Byetta is a rising star for Amylin and its partner, Eli Lilly and Co. The two companies split revenues, which were $650.2 million last year.
The diabetes market is massive and growing. Diabetes is the fifth-leading cause of death in the United States, affecting 20 million people.
But sales of Byetta, which once grew by triple-digit percentages, have begun to stagnate.
To put some punch back into Byetta, Amylin and Indianapolis-based Lilly are developing a once-weekly version, called exenatide LAR. Wall Street is hoping the version will become more popular than the standard, twice-a-day version of Byetta now on the market, propelling it to multibillion-dollar blockbuster status.
The companies plan to submit the drug for approval next year.
More
The diabetes market is massive and growing. Diabetes is the fifth-leading cause of death in the United States, affecting 20 million people.
But sales of Byetta, which once grew by triple-digit percentages, have begun to stagnate.
To put some punch back into Byetta, Amylin and Indianapolis-based Lilly are developing a once-weekly version, called exenatide LAR. Wall Street is hoping the version will become more popular than the standard, twice-a-day version of Byetta now on the market, propelling it to multibillion-dollar blockbuster status.
The companies plan to submit the drug for approval next year.
More
But........
2 comments:
Creating more strict standards regarding FDA approval is preferred over approving a medication prematurely and causing death and injury. I believe most would agree with this.
I have been a using the LAR for over a year with no negative side effects and greatly improved A1c ( from 7.2 to 6.2), 30 pounds weight loss, and not feeling hungry all the time.
Post a Comment